OncLive TV

Sara A. Hurvitz, MD, discusses the benefit of trastuzumab deruxtecan in a subset of patients with HER2-positive breast cancer and active brain metastases in the phase 3 DESTINY-Breast03 trial.

Sara M. Tolaney, MD, MPH, discusses pivotal trials in HER2-positive breast cancer.

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss next steps with CAR T-cell therapy.

Brian Ramnaraign, MD, discusses sequencing immunotherapy and tyrosine kinase inhibitor combinations in metastatic renal cell carcinoma.

Lori A. Leslie, MD, discusses the methods utilized in the phase 3 ZUMA‑7 trial in relapsed/refractory large B-cell lymphoma.

Sara A. Hurvitz, MD, discusses the clinical implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

Alessandra Larocca, MD, PhD, discusses what to know when diagnosing difficult-to-treat patients with multiple myeloma.

David Siegel, MD, PhD, Noa Biran, MD, and David H. Vesole, MD, PhD, discuss key takeaways from ASH 2021.

David Siegel, MD, PhD, Noa Biran, MD, and David H. Vesole, MD, PhD, discuss ongoing clinical trials in multiple myeloma.

Rohan Jeyarajah, MD, discusses the potential role of SIR-Spheres® Y-90 resin microspheres from Sirtex Medical in colorectal cancer with liver metastases.

Patrick Borgen, MD, discusses the evolution of immuno-oncology clinical trials in breast cancer.

Debu Tripathy, MD, discusses the emergence of genomics research in breast cancer.

Sara A. Hurvitz, MD, discusses utilizing CDK4/6 inhibitors in hormone receptor-positive breast cancer.

Sara M. Tolaney, MD, MPH, discusses the efficacy of trastuzumab deruxtecan in the second-line setting and its potential to move into the first-line treatment of HER2-positive breast cancer.

Sundar Jagannath, MBBS, discusses the FDA approval of ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

Jason R. Westin, MD, director, discusses the utilization of CAR T-cell therapy in relapsed/refractory large B-cell lymphoma.

David S. Hong, MD, discusses the primary objective of the ongoing phase 1/2 CodeBreaK 101 trial in mutated advanced colorectal cancer and other solid tumors harboring KRAS G12C mutations.

Toni Choueiri, MD, discusses the design of the phase 3 KEYNOTE-564 trial in renal cell carcinoma.

Zeynep Eroglu, MD, discusses the utilization of circulating tumor DNA in patients with melanoma.

Tiffany A. Traina, MD, discusses the implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

Wade T. Iams, MD, discusses the key implications of the phase 3 ADAURA trial in non–small cell lung cancer.

Jan A. Burger, MD, PhD, discusses the current landscape of CAR T-cell therapy in chronic lymphocytic leukemia.

Ruben A. Mesa, MD, discusses the accelerated FDA approval of pacritinib (Vonjo) for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.

Edmund Scott Kopetz, MD, PhD, FACP, discusses the utilization of circulating tumor DNA in colorectal cancer.

Michael Wang, MD, discusses adverse effects associated with BTK inhibitors in patients with mantle cell lymphoma.

Roberto Iacovelli, MD, PhD, discusses the rationale of the phase 2 ARIES trial in urothelial cancer.

Kanwal P.S. Raghav, MBBS, MD, discusses on the utilization of circulating tumor DNA in metastatic colorectal cancer.

Mohammed Milhem, MBBS, MBBS, discusses the utility of vusolimogeneoderparepvec in solid tumors.

Michael Wang, MD, discusses potential adverse effects associated with ibrutinib in patients with mantle cell lymphoma.

Stephen Oh, MD, PhD, discuses the evolving treatment landscape of chronic lymphocytic leukemia.